While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Ulcerative pyoderma gangrenosum is a rare disease with ...
JENA, Germany, May 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that ...
Multi-national, randomized, controlled adaptive Phase III study in ulcerative pyoderma gangrenosum (PG) initiated and first patient dosed in the U.S. PG is a rare and debilitating autoimmune skin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback